IL-17 Inhibition in Spondyloarthritis Associates with Subclinical Gut Microbiome Perturbations and a Distinctive IL-25-Driven Intestinal Inflammation
- Autori: Manasson, Julia; Wallach, David S; Guggino, Giuliana; Stapylton, Matthew; Badri, Michelle H; Solomon, Gary; Reddy, Soumya M; Coras, Roxana; Aksenov, Alexander A; Jones, Drew R; Girija, Parvathy V; Neimann, Andrea L; Heguy, Adriana; Segal, Leopoldo N; Dorrestein, Pieter C; Bonneau, Richard; Guma, Monica; Ciccia, Francesco; Ubeda, Carles; Clemente, Jose C; Scher, Jose U
- Anno di pubblicazione: 2020
- Tipologia: Articolo in rivista
- Parole Chiave: Candida; IL-17 inhibitor; Microbiome; Psoriatic arthritis; Spondyloarthritis
- OA Link: http://hdl.handle.net/10447/399844
Abstract
To characterize the ecological effects of biologic therapies on the gut bacterial and fungal microbiome of psoriatic arthritis (PsA)/spondyloarthritis (SpA) patients.